ERBB2 and breast cancer: BC subtypes that express ER and/or show Her2 amplification are effectively treated by therapies that target these receptors; as a result, TNBC, which is identified by the absence of these actionable targets, currently has no approved targeted therapies for use outside of clinical trials and is primarily managed with cytotoxic chemotherapy, radiation, and surgery [3,4].